General Research Interest
Our laboratory is working on the cancer biology and cancer therapy of STAT3 pathway in human cancer.Research Description
STAT3 is frequently activated in many types of human cancer and play a role in cancer progression. STAT3 is recognized as an attractive therapeutic target. Our research focus is to develop small molecular inhibitors that target JAK2/STAT3 and IL-6/STAT3 as novel therapeutic target approaches in solid and blood cancers.Transinstitutional Work
Collaborators to develop novel STAT3 and IL-6 inhibitors:
Tom Li, Ph.D. (Division of Medicinal chemistry, College of Pharmacy)
Chenglong Li, Ph.D. (Division of Medicinal chemistry, College of Pharmacy)
Jim Fuchs, Ph.D. (Division of Medicinal chemistry, College of Pharmacy)
Gregory Lesinki, Ph.D. (Internal Medicine, College of Medicine)